Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Bronchiolitis Obliterans.
Tackling administrative harm can yield better decisions for better care
Awareness of the harms to patients caused by errors in diagnosis and treatment has been front and center for nearly 25 years. A different kind